Straits Times Index
3,331.24 +0.43 (+0.01%) Nikkei
38,683.93 -19.58 (-0.05%) Hang Seng
18,336.09 -140.71 (-0.76%) FTSE 100
8,266.96 -18.38 (-0.22%) Bitcoin USD
71,062.87 +55.58 (+0.08%) CMC Crypto 200
1,481.81 +3.10 (+0.21%)
APLS Jun 2024 50.000 call
| Previous close | 0.2000 |
| Open | 0.2800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 50.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.1800 - 0.2800 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireApellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abou
ZacksApellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
